Table. 2.

Baseline characteristics and clinical outcomes of pancreatic cystic lesions

Characteristic SOT group (n=15) Control group (n=60) P-value
Type of PCL 0.150
SCA 4 (26.7) 24 (40.0)
MCN 1 (6.7) 3 (5.0)
IPMN 6 (40.0) 29 (48.3)
Pseudocyst 4 (26.7) 4 (6.7)
Number 0.753
Single 13 (86.7) 50 (83.3)
Multiple 2 (13.3) 10 (16.7)
Location 0.057
Head 6 (40.0) 20 (33.3)
Body 0 17 (28.3)
Tail 9 (60.0) 23 (38.3)
Cyst size (cm)
At diagnosis 2.40±2.07 2.01±1.07 0.497
At last imaging 2.00±2.02 1.96±1.22 0.909
Cyst change 0.007
Increase 2 (13.3) 18 (30.0)
Decrease 6 (40.0) 5 (8.3)
No change 7 (46.7) 37 (61.7)
Worrisome feature
Cyst symptoma) 0 0 -
Mural nodule 0 1 (1.7) 1.000
MPD dilatation 2 (13.3) 3 (5.0) 0.260
Follow-up (mo) 56.40±36.71 41.73±28.80 0.100

Values are presented as number (%) or mean±standard deviation.

SOT, solid organ transplantation; PCL, pancreatic cystic lesion; SCA, serous cystadenoma; MCN, mucinous cystic neoplasms; IPMN, intraductal papillary mucinous neoplasm; MPD, main pancreatic duct.

a)Cyst-abdominal pain or discomfort, bleeding.

Korean J Transplant 2022;36:197~202 https://doi.org/10.4285/kjt.22.0020
© Korean Journal of Transplantation